EDRN Prostate MRI Biomarker Study and Reference Set
University of Michigan
Summary
The commercialization of MRI fusion biopsies has resulted in a dramatic increase in the use of MRI imaging for prostate cancer. How best to use MRI in the initial prostate biopsy setting given the availability of validated prostate cancer early detection markers is uncertain.This study will allow investigators to determine if prostate MRI is superior to validated panel of laboratory biomarkers (e.g. PCA3, PSA and TMPRSS2:ERG) in the initial biopsy setting.
Description
The primary aim of this study is to see if the addition of prostate MRI to a panel consisting of PSA, PCA3, TMPRSS2:ERG will significantly improve specificity for high-grade prostate cancer by 10%. The subsequent exploratory aims will 1) create an optimal panel of urine, blood and tissue biomarkers that will select those cases most likely to benefit from a MRI targeted biopsy, 2) directly compare PSA and urinary biomarkers with MRI to determine which ones are value added in the setting of initial biopsy, 3) evaluate changes in these biomarkers and MRI to determine if longitudinal changes predi…
Eligibility
- Age range
- 18+ years
- Sex
- Male
- Healthy volunteers
- No
Inclusion Criteria: * Men with suspected but undiagnosed prostate cancer * To be scheduled/scheduled for biopsy as routine clinical care Exclusion Criteria: * Inability to obtain blood and urine per SOP or conduct an attentive DRE * Unable to undergo/tolerate a prostate MRI or failure to conduct the MRI * Prior diagnosis of prostate cancer * Prior prostate MRI unless being used as Index MRI (in this case index MRI can be one year prior to consent date) * Participating in clinical trial for prostate disease * Prior prostate surgery such as TURP, TUNA, TUMT, HOLEP, REZUM, UROlift * Prior PCA3…
Interventions
- Diagnostic TestMRI prostate
MRI and laboratory biomarkers
Location
- University of MichiganAnn Arbor, Michigan